在三门峡治疗男人腋臭的医院三门峡如何治疗壮疙瘩,三门峡治痘痘有哪些,三门峡如何快速修复痘痘,三门峡去哪里治疗聚合型痘痘,三门峡快速清除痘痘的方法,三门峡狐臭 什么医院好,三门峡用激光治疗腋臭

COPENHAGEN, May 29 (Xinhua) -- The number of confirmed E.coli cases has risen to 11 with at least another eight persons suspected of having the intestinal infection in Denmark, according to Denmark's National Serum Institute on Sunday.Five of the confirmed cases show symptoms of kidney failure which marks an advanced stage of the sickness, the institute said.Danish cucumbers are suspected of helping spread the E. coli bacteria believed to be causing a deadly outbreak of intestinal infection in Denmark and Germany, local media reported Sunday.The Danish cucumbers were mixed in Germany with cucumbers originating in the Netherlands, making it difficult to determine if Danish cucumbers are in fact contaminated.Denmark's Veterinary and Food Administration (DVFA) had earlier said the suspicion against Danish cucumber was "vague", but advised Danish consumers not to eat raw tomatoes, lettuces and cucumbers from Germany, and cucumber from Spain.It is now checking Danish cucumbers for traces of E. coli with results expected on Tuesday.Some Danish retailers have now removed these products from their supermarket shelves. And the Danish branch of fast-food chain McDonald's announced Saturday that it was dropping fresh cucumbers from its menu until further notice.The infection, which is food-borne, can be caused by eating raw or uncooked foods such as vegetables contaminated with the E. coli bacteria.Symptoms of infection include mild fever, bloody diarrhea and vomiting, and can last five to seven days. It can prove fatal in the very young, sick, or elderly.

WASHINGTON, July 26 (Xinhua) -- The District of Columbia Department of Health (DOH) in the U.S. announced Tuesday that it has positively identified the West Nile Virus in mosquito samples in the District.This is the first time this summer the West Nile Virus has been identified in the U.S. capital."Residents should take caution as mosquitoes have the potential to transmit West Nile Virus to humans, and it is important for residents to take the necessary steps to avoid contracting the virus," DOH said in a statement.West Nile Virus is mainly an infection of birds, but on occasions an infected mosquito may spread it to humans. The virus is not transmitted directly from birds to humans and the risk of infection is low. In human infections, the virus generally causes no symptoms, or may cause mild flu-like symptoms.Senior citizens and people with weak immune systems are considered high risk for suffering the worst from the disease, officials said."People with a higher risk of infection should wear long- sleeved shirts, long pants, and apply insect repellent with DEET or other mosquito repellents to exposed skin according to manufacturer's directions. For children, they should use a product with DEET concentration of less than 30 percent," DOH said.

LOS ANGELES, June 5 (Xinhua) -- U.S. researchers have developed two new drugs that can prolong the lives of patients with advanced melanoma, it was announced on Sunday.Research on both drugs was presented at the on-going annual meeting of the American Society of Clinical Oncology in Chicago, according to HealthDay News.This is the first big news in years for treatment of melanoma, one of the deadliest forms of skin cancer and one that is notoriously difficult to treat, let alone cure, the report said.The first treatment, vemurafenib, inhibits a gene mutation harbored in half of all melanoma patients, but is not yet approved by the U.S. Food and Drug Administration.The other drug, Yervoy (ipilumumab), is an immune system therapy that won approval in March."The March FDA approval of ipilumumab (Yervoy) was the first new drug approval for melanoma in 13 years," said Tim Turnham, executive director of the Melanoma Research Foundation.The two drugs were developed by researchers at Memorial Sloan- Kettering Cancer Center in New York City, the report said."This is really a huge step toward personalized care in melanoma," Dr. Paul Chapman, lead author of the first study and the attending physician in the melanoma/sarcoma service at Memorial Sloan-Kettering, said in a statement. "This (vemurafenib) is the first successful melanoma treatment tailored to patients who carry a specific gene mutation in their tumor, and could eventually become one of only two drugs available that improves overall survival in advanced cancers.""Having two trials that show a benefit in survival in patients with melanoma, both of these in first-line settings -- we weren't here just a few years ago," said Dr. Stephen Hodi, director of the Melanoma Center at Dana Farber Cancer Institute in Boston. "These are huge, paradigm-shifting results for the field."In the vemurafenib trial, sponsored by the drug's makers, researchers randomly assigned 675 patients with advanced, inoperable melanoma to receive either the chemotherapy drug dacarbazine or vemurafenib. Vemurafenib targets the V600E mutation in the BRAF gene.At the three-month mark, patients taking vemurafenib were 63 percent less likely to die and 74 percent less likely to die or see their cancer return, compared to patients taking dacarbazine alone.Few patients had side effects in the vemurafenib group, although some did develop squamous cell carcinoma, a less dangerous form of skin cancer.This is the first drug that has been proven superior to chemotherapy in this group of hard-to-treat patients, the researchers said."There was such a substantial benefit that we recommended that patients cross over," Chapman said at a Sunday news briefing. "It' s unprecedented to report a trial this early. The median follow-up time was three months." Yet the differences between the two groups became evident almost immediately.Dr. Lynn Schuchter, co-moderator of the briefing and division chief of hematology-oncology at Abramson Cancer Center of the University of Pennsylvania in Philadelphia, said symptoms subsided in some patients almost immediately, enabling them to cut back on pain medication in just 72 hours."The median time to progression with dacarbazine was 1.6 months versus three months with vemurafenib, which is a huge difference," said Chapman.In the second study, about 500 patients were randomly picked to receive Yervoy plus dacarbazine or dacarbazine alone.Those taking both drugs lived a median of 11.2 months compared to 9.1 months for those taking dacarbazine alone. Time to recurrence of disease was about the same for both groups: 2.8 months and 2.6 months, respectively.Almost half of those taking the combination therapy were alive after one year, compared to 36.3 percent in the other group. After two years, the rates were 28.5 percent and 17.9 percent, respectively.By three years out, 20.8 percent of those in the combination group were alive compared with 12.2 percent of those taking chemotherapy alone.This is the first study to combine chemotherapy and immunotherapy both safely and effectively.A study to test vemurafenib in combination with Yervoy has already begun, according to HealthDay News.

SAN FRANCISCO, June 1 (Xinhua) -- Microsoft on Wednesday gave a preview of its next-generation operating system code-named "Windows 8."The software giant introduced the successor to Windows 7 at the ninth edition of The Wall Street Journal's Digital: All Things Digital in Rancho Palos Verdes, California, some 48 km south of Los Angeles.With an interface quite different from legacy Windows, Windows 8 looks more like Windows Phone 7 and features an app management from Windows mobile operating system. It is the first major attempt by Microsoft to expand a mobile operating system to desktop status, and is expected to be touch-friendly and work seamlessly on desktops, laptops and tablet computers.For legacy Windows users, they need to swipe up from the bottom of the screen to get to the Windows 7-based view. Microsoft said the new system will be compatible with all Windows 7 logo PCs, software and peripherals.During the demonstration, Steven Sinofsky, Microsoft's head of Windows, also said the importance of not abandoning the established technologies from the traditional PC. "The mouse and the keyboard aren't evil. They're just tools. There are a number of applications that require the greater precision offered by the mouse." said Sinofsky.Sinofsky did not say when Windows 8 would be available.Although there are some tablets running Microsoft's current Windows 7 operating system, the software giant has been criticized for failing to adequately respond to the fast growth of tablet computers, like Apple's iPad.

PARIS, Aug. 7 (Xinhua) -- European heavy-lift launcher Ariane 5 lifted off two communication satellites on Saturday.The Ariane 5, carrying Astra 1N and BSAT-3c/JCSAT-110R, was launched at 2252 GMT on Saturday from Kourou launch centre in French Guiana, according to live broadcast of the launching process.This was the fourth mission of Ariane 5 in 2011 and its 203th flight that sent off the two satellites Saturday night to their respective geostationary transfer orbits.Astra 1N, to be separated first, is built by EADS Astrium in Toulouse, France, for the Luxembourg-based operator SES Astra. With a designed lifespan of 15 years, it has an estimated liftoff mass of 5,350 kg and is fitted with 52 active Ku-band transponders.It is initially to deliver interim capacity from an orbital position of 28.2 degree East, and will subsequently move to SES Astra's prime location at 19.2 degree East for primary and backup services.BSAT-3c/JCSAT-110R is manufactured by Lockheed Martin Commercial Space Systems in Newtown, Pennsylvania, for Japanese operators B-SAT Corporation and SKY Perfect JSAT Corporation. This satellite weighs approximately 2,910 kg at launch time. It is to be positioned at 110 degree East longitude in geostationary orbit with a lifetime exceeding 16 years.This Ariane 5 flight has been postponed twice, firstly due to some technical problem in early July and then delayed by bad weather.Arianespace plans to achieve six Ariane 5 missions through this year.